APHA Adverse Event Monitoring & VAERS 3 — Questions and Answers
Question 1: A VAERS report submitted by a patient describes a reaction to a vaccine received 3 years ago. How should this report be handled?
- Rejected because it exceeds the 30-day reporting window
- Accepted, as VAERS has no strict time limit for report submission (Correct answer)
- Forwarded only to the FDA, not the CDC
- Accepted only if submitted by a healthcare provider
Correct answer: Accepted, as VAERS has no strict time limit for report submission
VAERS accepts reports at any time after vaccination; there is no expiration deadline for submitting a report.
Question 2: Which of the following best describes the purpose of the Brighton Collaboration in vaccine safety?
- To fund compensation for vaccine-injured patients in the United States
- To develop standardized case definitions for adverse events following immunization (Correct answer)
- To operate a national vaccine adverse event registry for developing countries
- To set immunization schedules for international travelers
Correct answer: To develop standardized case definitions for adverse events following immunization
The Brighton Collaboration creates standardized, evidence-based case definitions for adverse events to improve the consistency and comparability of vaccine safety data globally.
Question 3: During a mass vaccination campaign, a cluster of fainting episodes is observed at one clinic site. Which surveillance system is best designed to rapidly detect and investigate such a cluster signal?
- VAERS passive reporting alone
- The Clinical Immunization Safety Assessment (CISA) Project (Correct answer)
- The National Childhood Vaccine Injury Act database
- IIS (Immunization Information Systems)
Correct answer: The Clinical Immunization Safety Assessment (CISA) Project
CISA is designed for rapid clinical consultation and investigation of complex or clustered adverse event cases in coordination with CDC.
Question 4: A manufacturer receives spontaneous safety reports from post-marketing surveillance showing an unexpected neurological event in 3 out of 500,000 vaccinees. What is the manufacturer's regulatory obligation?
- No obligation unless 10 or more cases are reported
- Submit an expedited report to the FDA within 15 business days if the event is serious and unexpected (Correct answer)
- Wait for VAERS to identify the signal before acting
- Report only to the WHO within 30 days
Correct answer: Submit an expedited report to the FDA within 15 business days if the event is serious and unexpected
FDA regulations (21 CFR 600.80) require manufacturers to submit expedited 15-day safety reports for serious, unexpected adverse experiences identified post-licensure.
Question 5: Which statement correctly describes who can submit a VAERS report?
- Only licensed healthcare providers and vaccine manufacturers
- Anyone, including patients, parents, caregivers, and healthcare providers (Correct answer)
- Only the state or local health department
- Only the physician who administered the vaccine
Correct answer: Anyone, including patients, parents, caregivers, and healthcare providers
VAERS accepts reports from anyone, including patients and family members, though healthcare providers and manufacturers also have reporting obligations for certain events.
Question 6: When analyzing VAERS data, a researcher notices a proportional reporting ratio (PRR) of 4.5 for myocarditis after mRNA COVID-19 vaccination in males aged 12–17. What does this PRR indicate?
- Myocarditis is 4.5 times more common in the general population than in vaccinated individuals
- Myocarditis reports are 4.5 times more proportionally frequent after this vaccine/demographic combination than after other vaccines (Correct answer)
- 4.5% of vaccinated male adolescents developed myocarditis
- The vaccine caused myocarditis in exactly 4.5 per million doses
Correct answer: Myocarditis reports are 4.5 times more proportionally frequent after this vaccine/demographic combination than after other vaccines
A PRR measures disproportionality in reporting; a PRR of 4.5 means myocarditis appears 4.5 times more often proportionally for this group than for the comparison group, serving as a signal for further investigation.
Question 7: A provider notes that a patient experienced a severe local reaction (Arthus reaction) after their 5th dose of Td vaccine. Which action regarding VAERS reporting is most appropriate?
- No report needed because local reactions are always minor
- File a VAERS report because severe local reactions are reportable (Correct answer)
- Report only if the patient is hospitalized
- Defer reporting until the next annual vaccine safety review
Correct answer: File a VAERS report because severe local reactions are reportable
Severe local reactions such as Arthus reactions following Td are considered clinically significant and should be reported to VAERS.
APHA Adverse Event Monitoring & VAERS 3
A VAERS report submitted by a patient describes a reaction to a vaccine received 3 years ago.
How should this report be handled?